Veru, Inc. (VERU) Reports Q3, Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. DFTX

Go back to Veru, Inc. (VERU) Reports Q3, Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

August 11, 2022 6:30 AM EDT

--Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022--

--The UKs Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will Receive Expedited Review--

--European Medicines Agencys Emergency Task Force Initiated Review of Sabizabulin Treatment for Hospitalized COVID Patients for Emergency Use in European Union Countries--

--The New England Journal of Medicine Evidence® Published Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment... More